Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDDate | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
04/13/2023 | Q4 2022 | $0.18 | $0 | |||
11/14/2022 | Q3 2022 | $0.09 | $0 | |||
08/15/2022 | Q2 2022 | $0.07 | $0 | |||
05/23/2022 | Q1 2022 | $0.21 | $0 | |||
04/08/2022 | Q4 2021 | $0.69 | $0 | |||
11/22/2021 | Q3 2021 | $0.32 | $0 | |||
08/16/2021 | Q2 2021 | $0.15 | $0 | |||
07/16/2021 | Q1 2021 | $0.45 | $0 | |||
03/31/2021 | Q4 2020 | $0.00 | $0 |
Eucrates Biomedical Acquisition Corp. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, March 31st, 2021 based off last year's report dates.
The conference call for Eucrates Biomedical Acquisition Corp.'s latest earnings report can be listened to online.
The conference call transcript for Eucrates Biomedical Acquisition Corp.'s latest earnings report can be read online.
Eucrates Biomedical Acquisition Corp. (:EUCR) has a recorded net income of $0. Eucrates Biomedical Acquisition Corp. has generated $1.86 earnings per share over the last four quarters.
Eucrates Biomedical Acquisition Corp. (:EUCR) has a price-to-earnings ratio of 5.4 and price/earnings-to-growth ratio is 0.05.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED